1st, I merely stated what Dr. Javitt stated on his video.
2nd, his comment, nor my interpretation of it, ever stated that RLF100 did not activate VPAC2. That was an incorrect assumption made by you.
Dr. Javitt's statement appears to be 100% correct. He merely stated that RFL100 activites the VPAC1 receptor.
I believe that you are reading into his statement too much. Just take it at face value. What Dr Javitt said, as far as he took it, appears to be correct.
More important..... The PhaseBIO drug did NOT target the VPAC1 receptor. Which is most likely why it failed the trial. Dr Javitt appears to have predicted that gap/void via his his own words in that video. He is a very smart man who can read between the lines.
Market Data 
Markets 
AI
